Literature DB >> 29132956

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.

Marcus Maurer1, Allen Kaplan2, Karin Rosén3, Michael Holden3, Ahmar Iqbal3, Benjamin L Trzaskoma3, Ming Yang3, Thomas B Casale4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29132956     DOI： 10.1016/j.jaci.2017.10.018

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  11 in total

1.  Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018.

Authors:  Rachel L Miller; Maria Shtessel; Lacey B Robinson; Aleena Banerji
Journal:  J Allergy Clin Immunol       Date:  2019-06-24       Impact factor: 10.793

Review 2.  Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review.

Authors:  Benjamin Greiner; Savannah Nicks; Michael Adame; Jennifer McCracken
Journal:  Clin Rev Allergy Immunol       Date:  2022-09-01       Impact factor: 10.817

Review 3.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

Review 4.  Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic.

Authors:  Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo
Journal:  Curr Allergy Asthma Rep       Date:  2018-05-09       Impact factor: 4.806

Review 5.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

Review 6.  Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review.

Authors:  Melanie Mitsui Wong; Paul Kevin Keith
Journal:  Allergy Asthma Clin Immunol       Date:  2020-08-04       Impact factor: 3.406

7.  Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.

Authors:  Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez
Journal:  World Allergy Organ J       Date:  2019-02-23       Impact factor: 4.084

8.  A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.

Authors:  H Lapeere; M Baeck; A Stockman; V Sabato; M Grosber; M Moutschen; J Lambert; L Vandebuerie; L de Montjoye; H Rabijns; K Allewaert; R Schrijvers
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-08-19       Impact factor: 6.166

9.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

Review 10.  Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease.

Authors:  Sara Manti; Alessandro Giallongo; Maria Papale; Giuseppe Fabio Parisi; Salvatore Leonardi
Journal:  J Clin Med       Date:  2022-07-30       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.